# Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

> **NCT01549769** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 24 (actual)

## Conditions studied

- Renal Insufficiency, Chronic
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Bardoxolone Methyl

## Key facts

- **NCT ID:** NCT01549769
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04-30
- **Primary completion:** 2012-11-30
- **Final completion:** 2013-10-31
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** IDMC recommendation for safety concerns
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01549769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01549769, "Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01549769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*